TERA SCIENCE Co.,LTD: debt-to-equity, ROE and more
KOSDAQ, Legal name TERA SCIENCE Co.,LTD
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 96.7%
- Equity ratio
- 50.8%
- ROE
- -60.2%
- Op. margin
- -71.7%
- Rev. growth
- -18.2%
- Interest coverage
- n/a
Condition flags
- Latest operating profit is not above zero, or not reported.
- Operating loss for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 97.9% | 50.5% | -6.5% | -9.7% | n/a |
| FY2022 consolidated | 35.7% | 73.7% | 35.9% | -4.0% | 3.7% |
| FY2023 consolidated | 24.9% | 80.0% | -3.8% | -15.0% | 1.2% |
| FY2024 consolidated | 16.2% | 86.1% | -14.8% | -54.9% | -25.1% |
| FY2025 consolidated | 96.7% | 50.8% | -60.2% | -71.7% | -18.2% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩22.0B | ₩22.8B | ₩23.1B | ₩17.3B | ₩14.1B |
| Operating profit | -₩2.1B | -₩918.9M | -₩3.5B | -₩9.5B | -₩10.1B |
| Pre-tax income | -₩3.7B | ₩30.1B | -₩3.3B | -₩10.0B | -₩16.3B |
| Net income | -₩3.2B | ₩28.7B | -₩2.9B | -₩10.0B | -₩17.2B |
| Total assets | ₩97.7B | ₩108.5B | ₩94.5B | ₩78.5B | ₩56.3B |
| Total liabilities | ₩48.3B | ₩28.5B | ₩18.9B | ₩10.9B | ₩27.7B |
| Total equity | ₩49.4B | ₩80.0B | ₩75.6B | ₩67.6B | ₩28.6B |
| Paid-in capital | ₩7.4B | ₩8.3B | ₩9.6B | ₩10.6B | ₩10.6B |
| Debt/equity (source value) | 97.9% | 35.7% | 24.9% | 16.2% | 96.7% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1993-10-19
- Listed
- 04/01/06
- Employees
- 90
- Auditor
- 대주회계법인
- Audit opinion
- 의견거절
- Corporate reg. no.
- 1901110021119
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 테라사이언스Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.